Basilea's Cresemba™ Sales Surge Leads to Major Milestone Payment
Significant Sales Growth for Cresemba™ in Europe
Basilea Pharmaceutica Ltd has announced a remarkable achievement related to its antifungal drug, Cresemba™ (isavuconazole). Sales of this drug, marketed in Europe through its licensing partner Pfizer, have surpassed expectations, resulting in a milestone payment of USD 25 million to Basilea. This strong performance showcases not only the increasing demand for effective antifungal treatments but also the ability of Basilea to fulfill critical medical needs for patients suffering from serious fungal infections.
CEO Commentary on Sales Performance
David Veitch, the Chief Executive Officer of Basilea, expressed his satisfaction with the ongoing success of Cresemba. He stated, “We are very pleased with the continued recognition of Cresemba in meeting the crucial medical needs of patients with life-threatening invasive mold infections. The increase in sales performance in Europe has directly contributed to this milestone payment.” Veitch further highlighted several previous milestone payments from sales in the Asia Pacific region and China, underlining the global success of Cresemba.
A Broad Reach Across Markets
Basilea’s strategic licensing agreement with Pfizer encompasses not only Europe, excluding the Nordic countries, but also extends to 16 countries in the Asia Pacific region and China. Such an extensive reach allows for wider accessibility of Cresemba, approved for use in over 70 countries worldwide. This includes major markets like the United States and various EU nations, significantly contributing to reported global sales which reached USD 489 million for the twelve months ending March 2024.
About Cresemba™ and Isavuconazole
Isavuconazole, marketed as Cresemba™, is an innovative azole antifungal available in both intravenous and oral formulations. It serves as an essential treatment option for invasive fungal infections, particularly for conditions such as invasive aspergillosis and mucormycosis. Basilea holds multiple license agreements covering isavuconazole across approximately 115 countries, ensuring its availability within the healthcare systems of different regions. In the EU, isavuconazole is approved for patients as young as one year old, underscoring its importance in pediatric care as well.
The Mission of Basilea Pharmaceutica
Basilea, established in 2000 and headquartered in Switzerland, focuses on the discovery and commercialization of novel therapeutics aimed at treating severe infections caused by bacteria and fungi. The company has successfully launched two primary products: Cresemba for fungal infections and Zevtera for bacterial infections. In addition to these, Basilea maintains a diverse portfolio that includes various preclinical and clinical anti-infective compounds, solidifying its commitment to addressing critical healthcare needs.
Get in Touch with Basilea
For those interested in learning more about Basilea and its products, here's the contact information:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd
Hegenheimermattweg 167b
4123 Allschwil, Switzerland
Phone: +41 61 606 1102
Email: media_relations@basilea.com | investor_relations@basilea.com
Frequently Asked Questions
What is Cresemba™ used for?
Cresemba™ is an antifungal medication used to treat serious infections like invasive aspergillosis and mucormycosis.
Who is the licensing partner for Cresemba™ in Europe?
Pfizer is the licensing partner responsible for distributing Cresemba™ in Europe.
How much was the recent milestone payment to Basilea?
Basilea received a milestone payment of USD 25 million due to exceeding sales thresholds of Cresemba™.
In how many countries is Cresemba™ approved?
Cresemba™ is approved in more than 70 countries worldwide.
What are the primary focuses of Basilea Pharmaceutica?
Basilea focuses on developing and commercializing innovative treatments for severe bacterial and fungal infections.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Electric Hair Clippers and Trimmers Market Trends to 2033
- Kalmar Partners with Outokumpu for Sustainable Lift Solutions
- Outfit7's Commitment to Sustainability in Gaming
- Nio Stock: Why Analysts Are More Optimistic Moving Forward
- Market Trends Show Weakness in Major Indices and Opportunities
- Australian Stock Market Sees Gains as Key Sectors Rally
- Market Insights: Japan's Stocks and the Nikkei 225 Trends
- India's Markets Regulator Implements New Derivative Trading Rules
- Navigating the Divergence in US Economic Sectors
- Toyota Adjusts Global EV Production Forecast for 2026
Recent Articles
- Construction Contract for New Office Building in Tallinn
- TGS Launches Major 2D Seismic Survey in Sumatra Region
- Corporate Advancements of Bedford Metals in Uranium Exploration
- UGREEN's Exciting Uno Series Launches Innovative Chargers
- Japan's Business Leaders Monitor US Review of Steel Acquisition
- Big Lots Faces Financial Challenges as Analysts Adjust Targets
- Unlocking the Future of Finance: WSPN at TOKEN2049 Singapore
- Former Samsung Executive Faces New Theft Allegations in Korea
- Navigating Nvidia's Market Shift: A Buying Opportunity?
- Wall Street's Insights on U.S. Job Market and Fed Decisions
- Japan's Tax Debate: Implications for Investment Income
- Market Shifts: Bitcoin, Dogecoin Struggles, Solana's Potential Rise
- Exploring Dell Technologies' Potential Amid Growth Uncertainties
- Opportunities for Endava plc Investors Amid Class Action Suit
- Multiverse Launches AI Advisory Board to Transform Workforce Skills
- Transforming Healthcare: Insights from the Global Health Exhibition
- UOB Returns to GBP Covered Bond Market with Strong Issuance
- Qualcomm Considers Acquisition of Intel's Design Division
- Hong Kong Trading Suspension Due to Super Typhoon Yagi
- Telegram-Linked Cryptocurrencies Surge After Durov's Statement
- The Rising Popularity of Japanese Products in South Korea
- A Fresh Perspective on Bitcoin ETFs vs Gold ETFs Market Trends
- Bunker Hill Mining Announces Strategic Share Issuance Plan
- YPF S.A. Launches Exchange Offer for Senior Notes Up to $500M
- United Steelworkers Critique US Steel's Leadership Amid Deal Scrutiny
- Varonis Systems Secures $400 Million through Senior Notes
- The Future of 6G: Innovations and the Next Mobile Evolution
- Pampa Energía S.A. Announces Tender Results for Series 1 Notes
- China and Africa Collaborate for Shared Modernization Goals
- Billionaires Show Confidence in Retail Investments
- Paramount Global Executive Receives Massive Severance Package
- US Steel Shares Soar Amid Cleveland-Cliffs Acquisition Talk
- Market Sentiment Shifts Ahead of US Jobs Report
- Key Insights into Today's Top Stocks: Broadcom, Nio & More
- Revamping Real Estate Operations with DashLoops Mobile Platform
- POWERCHINA Advances Energy Cooperation at Zambia Forum
- POWERCHINA Enhances Energy Collaboration with Zambia
- Investigation Launched into STMicroelectronics: Key Insights
- Crypto Market Overview: Bitcoin and Ethereum Struggle
- Investors Can Take Charge in Extreme Networks Fraud Case
- Evergreen Corporation Merges with Forekast for AI Innovation
- Investigation Launch by Faruqi & Faruqi on PDD Holdings
- Market Reactions and Anticipations Ahead of Key Jobs Data
- Exploring the Expanding Gene Panel Market for the Future
- Prepare for Thrilling Scares at America's Finest Haunted Attractions
- Investigating Claims for Stellantis Investors by Faruqi & Faruqi
- Understanding Legal Investigations: Oddity Stock and Investor Rights
- Innovative Therapeutic Discoveries by Sciwind Biosciences
- China's Major Brokerage Merger Signals Industry Transformation
- Concerns Rise Over Trump and Musk's Efficiency Plans Amid Economic Risks